PARTNER SEARCH for HORIZON-MISS-2025-02-CANCER-04: Investigator-initiated multinational early-stage innovative clinical trials for paediatric cancer

Introduction

A proposal is being prepared looking into a robust 'first in class' Clinical Trial paediatric and adolescent patients with relapsed/refractory (R/R) acute myeloid leukaemia (AML). The consortium is already made up of leading institutions and companies from EU, US and Korea. The Project is co-coordinated by Chaperone Ventures Korea and The Cancer Research and Innovation Hub (CRIHM), Malta. Our partners include the University of Cambridge, the Polish Academy of Sciences, and the University of Malta, along with several prominent public and pre-IPO companies from Korea. This diverse team provides a comprehensive blend of expertise, from cutting-edge drug development to advanced data science.

The Project

We are applying to HORIZON-MISS-2025-02-CANCER-04: Investigator-initiated multinational early-stage innovative clinical trials for paediatric cancer. Deadline is 16 September 2025.

The project presents an international consortium a robust 'first in class' Clinical Trial paediatric and adolescent patients with relapsed/refractory (R/R) acute myeloid leukaemia (AML). TRAP1-Paed-AML, a multinational, investigator-initiated Phase I/II clinical trial, focuses on This trial evaluates the safety and efficacy of SB-U015, a first-in-class TRAP1 inhibitor, in combination with existing therapies like venetoclax and gilteritinib, with which it has shown strong synergistic effects in preclinical studies.

What We Seek

We are actively recruiting an additional EU-based consortium members / Partners to fill a pivotal role in helping us manage two critical work packages. We are looking for a partner with proven experience who can ensure seamless execution and support key areas where our current consortium needs to be strengthened.

1. Clinical Operations & Trial Execution

This partner will be a key contributor to our clinical operations, overseeing and assisting in the trial's implementation across our intended EU sites. The ideal partner will take the lead in ensuring the smooth progression of all regulatory and clinical trial processes. Key activities include:

- Site initiation and management
- Patient recruitment for both dose escalation and expansion cohorts
- Ensuring meticulous compliance with clinical protocols

We need a partner who can drive our team forward, filling the gaps in our operational framework to ensure a seamless and efficient trial.

2. Data Management, Biostatistics, & Open Science

This role is vital for the scientific integrity and reusability of our research. The selected partner will be responsible for:

- Delivering robust statistical analyses

- Ensuring all data adhere to FAIR principles (Findable, Accessible, Interoperable, Reusable)
- Managing the release of de-identified datasets and reproducible pipelines to platforms like UNCAN.eu

We require a partner with demonstrated experience in these tasks to guarantee the scientific rigor and open accessibility of our research outputs.

Contact:

Contact: Je Min Yoo jeminyoo@chaperone.ventures